Hemarina is a biotechnology company with a strong R&D activity. Our teams have a unique know-how, based on fifteen years of fundamental research. The results of our research are the subject of numerous scientific articles published in leading journals.
M101, a therapeutic oxygen carrier derived from Arenicola marina, decreased Porphyromonas gingivalis-induced hypoxia and improved periodontal healing
J Periodontol. - 2022
HEMO2life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study
Artificial Organs. - 2021
Characterization of a hyaluronic acid-based hydrogel containing an extracellularoxygen carrier (M101) for periodontitis treatment: an in vitro study
Int J Pharm. - 2021